Per-Lesion Analysis (Prostate Cancer)
| Lesion type | Examination | Sensitivity | Specificity | PPV | NPV | Accuracy |
| Extraskeletal lesions | 18F−/18F-FDG PET/CT | 100.0 | NA | 100.0 | NA | 100.0 |
| Whole-body MRI | 100.0 | NA | 100.0 | NA | 100.0 | |
| 18F−/18F-FDG PET/CT + whole-body MRI | 100.0 | NA | 100.0 | NA | 100.0 | |
| Skeletal lesions (osteoblastic) | 18F−/18F-FDG PET/CT | 100.0*† | 60.0 | 94.1 | 100.0 | 94.6 |
| Whole-body MRI | 65.4 | 40.0 | 85.0 | 25.0 | 61.3 | |
| Bone scintigraphy | 81.3 | 100.0 | 100.0 | 45.5 | 83.8 | |
| Bone scintigraphy + whole-body MRI | 100.0 | 40.0 | 88.5 | 100.0 | 89.3 | |
| 18F−/18F-FDG PET/CT + whole-body MRI | 100.0 | 0.0 | 82.1 | NA | 82.1 | |
| Total lesions | 18F−/18F-FDG PET/CT | 100.0‡ | 60.0 | 94.4 | 100.0 | 94.9 |
| Whole-body MRI | 76.0 | 40.0 | 86.4 | 25.0 | 70.0 | |
| Bone scintigraphy + whole-body MRI | 100.0 | 40.0 | 89.3 | 100.0 | 90.0 | |
| 18F−/18F-FDG PET/CT + whole-body MRI | 100.0 | 0.0 | 83.3 | NA | 83.3 |
NA = not applicable. 18F−/18F-FDG PET/CT showed significantly higher sensitivity than whole-body MRI (*P < 0.02) and bone scintigraphy (†P < 0.03) in evaluation of skeletal lesions. 18F−/18F-FDG PET/CT showed statistically significant higher sensitivity than whole-body MRI (‡P < 0.02)